4 stories mentioning SHA:688428Updated 20d ago
Every FINWIRES story that references SHA:688428, newest first.
InnoCare Pharma (SHA:688428, HKG:9969) said China's drug regulator accepted the new drug application for orelabrutinib for treating primary immune thrombocytopenia (ITP), according to a Friday filing with the Shanghai bourse.Shares of the drugmaker rose 3% in recent trade on the Hong Kong bourse.
InnoCare Pharma (SHA:688428, HKG:9969) approved the vesting of shares under a stock incentive plan and the cancellation of granted but unvested shares, according to a Tuesday filing with the Shanghai bourse.The company will vest more than 2.4 million restricted shares granted to 74 recipients.InnoCare will cancel 157,000 shares that are granted but unvested, as the four recipients have departed InnoCare, and cancel 167,000 restricted shares.
InnoCare Pharma Ltd. (HKG:9969) unit InnoCare Pharma Inc. dosed the first subject in a phase 1 trial of ICP-054 in China.Preclinical data shows the potential of ICP-054 to be a differentiated oral therapy for autoimmune and inflammatory diseases associated with dysregulated IL-17 signaling, according to a Wednesday Hong Kong bourse filing.The Hong Kong-listed drugmaker is developing the drug in partnership with Zenas BioPharma.
InnoCare Pharma (SHA:688428, HKG:9969) recorded a 489% surge in attributable profit in the first quarter of 2026 to 105.8 million yuan from 18 million yuan a year prior, according to a Thursday Hong Kong bourse filing.Basic EPS rose to 0.06 yuan in the three months from 0.01 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 39% to 528.6 million yuan from 381.3 million yuan in the year-ago period, driven by the volume growth and new contributions from various products, as well as milestone payments under a license agreement with Zenas BioPharma.
